Create stable, long-term investment portfolio with strong, consistent stocks.
Start Research-backed Investing ...Now.
Dr Reddy’s is currently trading at Rs 1501.60, up by 18.45 points or 1.24% from its previous closing of Rs 1483.15 on the BSE.
The scrip opened at Rs 1486.00 and has touched a high and low of Rs 1510.00 and Rs 1481.05 respectively. So far 10739 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 1855.00 on 09-Dec-2010 and a 52 week low of Rs 1387.00 on 22-Aug-2011.
Last one week high and low of the scrip stood at Rs 1544.80 and Rs 1474.00 respectively. The current market cap of the company is Rs 25143.32 crore.
The promoters holding in the company stood at 25.62% while Institutions and Non-Institutions held 39.51% and 15.85% respectively. Dr Reddy's Laboratories’ proposed business deal to acquire the pharmaceutical prescription portfolio of JB Chemicals & Pharmaceuticals (JBCPL) in Russia and other CIS countries has been mutually terminated in the overall business interest of both parties.
Dr. Reddy's and JBCPL had entered into an agreement on July 22, 2011. Russia is one of Dr. Reddy's focus markets where it will continue to improve its market ranks and are committed to expanding its presence in the region.
Recently, the company had launched rivastigmine tartrate Capsules (1.5 mg, 3 mg, 4.5 mg and 6 mg), a bioequivalent generic version of Exelon capsules in the US market on September 15, 2011 following the approval by the United States Food & Drug Administration (USFDA) of the company’s Abbreviated New Drug Application (ANDA) for rivastigmine tartrate capsules.
Dr. Reddy's Laboratories is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1462.50 |
| Dr. Reddys Lab | 5784.50 |
| Cipla | 1451.25 |
| Zydus Lifesciences | 1001.15 |
| Lupin | 1587.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
